Stephen Willey

“I would just like to echo my appreciation to Claire and I, and congrats to everyone on the new appointments. Maybe just a couple of questions.”

“So just given what we know about truprothedal dose dependency, can you comment on how your powering into phase three T-PIP trials might contemplate the percentage of patients that you're expecting to be titrated up to the highest of all the 80 dose and are you expecting those percentages to be meaningfully different…”

“So, it sounds like you are in discussion with FDA around potentially modifying the event threshold for the interim. Just curious if there's been any contemplation of altering the threshold.”

“Please go ahead. yeah good afternoon thanks for taking the questions um so i guess persistency with um with oral tkis has made in therapy has historically been you know somewhat challenging across a number of different tuber types for various agents i think mostly related to reasons that uh uh that pj cited when he…”

“So I guess Nick Pinbo's sequential growth has kind of flattened out here over the past couple of quarters.”